Properties
What is it?
Name - Dinapar AQ IM IV Solution for Injection 75mg/1ml 1ml #5 Pharmacodynamic Properties Diclofenac is a non-steroidal agent with pronounced analgesic and anti-inflammatory properties. It is a prostaglandin synthesis inhibitor. Pharmacokinetic Properties Following intramuscular administration of Dinapar AQ, the mean peak plasma concentration is approximately 2.4 mcg/ml, reached within 49 minutes. Diclofenac is more than 99% bound to serum proteins, primarily albumin. Approximately 60% of the administered dose is excreted in the urine. The mean elimination half-life is 1.25 hours. Therapeutic Indications Intramuscular injection (intragluteal and intradeltoid) and intravenous infusion Dinapar AQ is effective in acute forms of pain, including renal colic, exacerbations of osteoarthritis and rheumatoid arthritis, acute back pain, acute gout, acute trauma and fractures, and postoperative pain. Intravenous bolus injection For acute postoperative pain, renal colic, and acute gouty arthritis. Dosage and Administration As a general recommendation, the dose should be individually adjusted and the lowest effective dose should be prescribed for the shortest possible duration. The recommended maximum daily dose of diclofenac is 150 mg. Dinapar AQ injection should not be administered for more than two days. Use in Special Populations Diclofenac is contraindicated in the last trimester of pregnancy and in children. Diclofenac should be avoided during breastfeeding. Geriatric use: The lowest effective dose should be used for the shortest possible duration. Patients on NSAID therapy should be regularly monitored for gastrointestinal bleeding. Contraindications • Active or history of recurrent peptic ulcer/bleeding (two or more distinct episodes of confirmed ulceration or bleeding); • Severe heart failure, moderate or severe renal failure, and liver disease; • Last trimester of pregnancy; • History of gastrointestinal bleeding or perforation related to previous NSAID therapy; • NSAIDs are contraindicated in patients who have previously exhibited hypersensitivity reactions to ibuprofen, aspirin, or other NSAIDs.